HomeGeneticsConditionSuccinic semialdehyde dehydrogenase deficiency
Back to Condition
Succinic semialdehyde dehydrogenase deficiency
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Succinic semialdehyde dehydrogenase deficiency

Succinic semialdehyde dehydrogenase deficiency is a neurological disorder characterized by developmental delays, intellectual disabilities, and decreased muscle tone, often accompanied by seizures and behavioral problems.

Overview

Succinic semialdehyde dehydrogenase deficiency is a disorder that can cause a variety of neurological problems. People with this condition typically have developmental delays, especially in speech development; intellectual disabilities; and decreased muscle tone (hypotonia) soon after birth. Communication problems may improve over time in people with this disorder.

About half of people with succinic semialdehyde dehydrogenase deficiency experience seizures, difficulty coordinating movements (ataxia), decreased reflexes (hyporeflexia), and behavioral problems. The most common behavioral problems associated with this condition are sleep disturbances, hyperactivity, difficulty maintaining attention, and anxiety. Other behavioral and psychiatric features, including aggression and obsessive-compulsive disorder (OCD), tend to develop in adolescence and early adulthood.

Frequency

Approximately 350 people with succinic semialdehyde dehydrogenase deficiency have been reported worldwide.

Causes

Variants (also called mutations) in the ALDH5A1 gene cause succinic semialdehyde dehydrogenase deficiency. The ALDH5A1 gene provides instructions for producing the succinic semialdehyde dehydrogenase enzyme. This enzyme is involved in the breakdown of a chemical that in the brain (neurotransmitter) called gamma-amino butyric acid (GABA). The primary role of GABA is to prevent the brain from being overloaded with too many signals.

ALDH5A1 gene variants lead to a shortage (deficiency) of succinic semialdehyde dehydrogenase. This deficiency results in an increase in the amount of GABA and a related molecule called gamma-hydroxybutyrate (GHB) in the body, which affects the brain. It is unclear how an increase in GABA and GHB causes developmental delays, seizures, and other signs and symptoms of succinic semialdehyde dehydrogenase deficiency.

Inheritance

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell must have a variant to cause the disorder. The parents of an individual with an autosomal recessive condition each carry one copy of the altered gene, but they typically do not show signs and symptoms of the condition.

Other Names for This Condition

  • 4-hydroxybutyric aciduria
  • Gamma-hydroxybutyric acidemia
  • Gamma-hydroxybutyric aciduria
  • SSADH deficiency

Frequently Asked Questions

bout half of individuals with succinic semialdehyde dehydrogenase deficiency experience seizures, which can vary in type. Management typically involves anti-seizure medications tailored to the individual's specific seizure type and frequency. Regular neurological evaluations, including electroencephalograms (EEGs), are important to monitor seizure activity and adjust treatment as needed.
Succinic semialdehyde dehydrogenase deficiency leads to a buildup of gamma-amino butyric acid (GABA) and gamma-hydroxybutyrate (GHB) in the brain. GABA is a neurotransmitter that normally calms brain activity, but its excess, along with GHB, disrupts normal brain function, contributing to developmental delays, seizures, and behavioral problems. While direct treatments targeting these specific chemical imbalances are still being researched, some therapies aim to modulate neurotransmitter activity or manage symptoms.
Parents should closely monitor for developmental delays, especially in speech, as well as intellectual disabilities and decreased muscle tone (hypotonia) from an early age. Behavioral changes to watch for include sleep disturbances, hyperactivity, difficulty maintaining attention, and anxiety. If these issues are observed, early intervention therapies like speech, occupational, and physical therapy, along with behavioral support, should be sought promptly.
The long-term outlook varies, but individuals typically experience lifelong neurological challenges. While communication problems may show some improvement over time, intellectual disabilities and motor difficulties like ataxia often persist. Behavioral and psychiatric features, such as aggression and obsessive-compulsive disorder (OCD), tend to emerge or worsen in adolescence and early adulthood, requiring ongoing management and support.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA